# Myeloma-Developing Regimens Using Genomics (MyDRUG)

> **NCT03732703** · PHASE1,PHASE2 · COMPLETED · sponsor: **Multiple Myeloma Research Consortium** · enrollment: 103 (actual)

## Conditions studied

- Relapsed Refractory Multiple Myeloma

## Interventions

- **DRUG:** Abemaciclib, dexamethasone, ixazomib, pomalidomide
- **DRUG:** Enasidenib, dexamethasone, ixazomib, pomalidomide
- **DRUG:** Cobimetinib, dexamethasone, ixazomib, pomalidomide
- **DRUG:** Erdafitinib, dexamethasone, ixazomib, pomalidomide
- **DRUG:** Venetoclax, dexamethasone, ixazomib, pomalidomide
- **DRUG:** Daratumumab, dexamethasone, ixazomib, pomalidomide
- **DRUG:** Belantamab mafodotin, dexamethasone, ixazomib, pomalidomide
- **DRUG:** Selinexor, dexamethasone, ixazomib, pomalidomide

## Key facts

- **NCT ID:** NCT03732703
- **Lead sponsor:** Multiple Myeloma Research Consortium
- **Sponsor class:** NETWORK
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-04-01
- **Primary completion:** 2024-12-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 103 (ACTUAL)
- **Last updated:** 2025-02-14

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03732703

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03732703, "Myeloma-Developing Regimens Using Genomics (MyDRUG)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03732703. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*